Fourth dose of BNT162b2 prevents severe COVID-19 in nursing home residents
Jun 27, 2022
Substantial protection against hospitalizations and deaths seen among nursing home residents during the omicron surge.
In 11 states, seniors’ low vaccination rates a ‘powder keg’ for new cases
Jun 21, 2021
In states where vaccination rates are low, seniors who have not gotten a shot pose a public health risk as social-distancing restrictions are stripped away.
COVID-19 vaccine booster dose cuts infection in those 60 and older
Sep 17, 2021
A large Israeli study shows a reduction in confirmed infection and severe illness among adults 60 years of age and older.
Pfizer has two updated booster shots to help fight omicron
Jun 27, 2022
The company said Saturday that it was confident that its new booster candidates are better than their predecessor.
Potential safety concern for Guillain-Barré syndrome ID’d for Ad26.COV2.S
Oct 18, 2021
Receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine is associated with a potential small, but statistically significant, safety concern for Guillain-Barré syndrome (GBS), according...
Pfizer study reveals big rise in immunity from COVID-19 booster
Nov 04, 2022
The FDA says the findings affirm its decision to approve the booster without human testing based on experience with a similarly tweaked vaccine.
Third, fourth COVID-19 vaccine doses boost humoral response in seniors
Jul 27, 2022
Third and fourth doses were tied to significantly increased anti-S IgG titers in older adults, but optimal timing of additional doses is not known.
Last week, the White House said local pharmacies are now providing more than two-thirds of COVID-19 vaccinations.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Third mRNA vaccine dose ups effectiveness against hospitalization
Jan 27, 2022
Vaccine effectiveness against COVID-19 hospitalization is increased with a third dose in those with or without immunocompromising conditions.